A european consortium with research teams from 11 different european sites, to develop clinical trials in order to prevent or delay Alzheimer’s disease in the population with Down syndrome.
The Horizon 21 Consortium was born from a collaboration between clinicians from various european centers offering a consultation dedicated to adults and seniors with Down syndrome.
This program aims at identifying the factors that influence the development of Alzheimer’s disease in persons with Down syndrome. The consortium wants also to develop cognitive assesment tools and biomarkers which could be relevant for clinical trials. Of course, the main objective is to prevent and/or delay the onset of Alzheimer’s disease in this specific population.
First PPI Meeting of the H21 Consortium On October 22, 2024, the first meeting of the Patient and Public Involvement (PPI) group was held online as part of the Horizon 21 (H21) research consortium. This marked a significant milestone, as it was the first H21 event to actively involve patients in the development of the research project, following the well-established […]
Honorary member of the Horizon 21 consortium, Tonnie Coppus was rewarded on Friday April 25 for special services to the society. During all her life, she has made an exceptional contribution on a national and international level to improving medical care for adults with Down syndrome. Her service has also focused on caregivers. She put issues on the map that others […]
The Horizon 21 team met up in Dublin on the 16th and 17th of May 2024, to discuss the first results of the longitudinal study of early markers of AD in adults with trisomy 21 (Horizon 21 cohort). The photo was taken in front of the Trinity College of Dublin. The next reunion will be in October, in Rome!
Each MRI is performed when the patient is completely relaxed. At the slightest sign of anxiety, the MRI is postponed. Several solutions are offered to help patients relax, such as the use of headphones to play a playlist of music created by the patient prior to the examination; the possibility of communicating with doctors during the MRI; and other solutions […]
The Horizon 21 research consortium met these 20th and 21st of october, in Paris, at the Institut Jérôme Lejeune. It was a great opportunity to share updates on current projects and to work together. The consortium gathers doctors and researchers from several European centers and conducts research projects on the prevention of Alzheimer’s disease in Down syndrome population.
Large-scale genotyping of persons with Down syndrome in order to identify risk or protective factors of Alzheimer's disease.
Harmonisation of cognitive evaluation tools
e.g neurofilaments light analysis in plasma.
Impact of Alzheimer’s disease on sleep of adults with Down syndrome.